New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
09:32 EDTOGXIOncoGenex announces initiation of Phase 2 OGX-427 study with Zytiga
OncoGenex Pharmaceuticals announced the initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer who are experiencing a rising PSA while receiving Zytiga. The aim of the study is to determine if adding OGX-427 to Zytiga treatment can reverse or delay treatment resistance. The primary objective will be to compare the two treatment groups for delaying further disease progression while on Zytiga by assessing the progression-free survival rate at 60 days after adding OGX-427. Secondary objectives include comparing the treatment arms for PSA responses, objective responses, time to progression, circulating tumor cells and other biomarkers.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 14, 2015
16:10 EDTOGXIOncoGenex sees reporting data from phase 2 Pacific trial in 2015
Subscribe for More Information
16:08 EDTOGXIOncoGenex sees sufficient cash to fund operations into 3Q16
Subscribe for More Information
16:06 EDTOGXIOncoGenex reports Q1 EPS (20c), three estimates (34c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use